Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Incyte Corp Drug Patent Portfolio

Incyte Corp's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Incyte Corp:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Incyte Corporation NA TERMINATED
(Sep 1, 2026)
PHASE1
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Incyte Corporation NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Incyte Corporation NA COMPLETED
(Aug 1, 2026)
PHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. Incyte Corporation NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma Incyte Corporation NA TERMINATED
(Jul 1, 2026)
PHASE3
Study of INCB123667 in Subjects With Advanced Solid Tumors Incyte Corporation NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. Incyte Corporation NA COMPLETED
(Jun 1, 2026)
PHASE2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Incyte Corporation NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants Incyte Corporation NA COMPLETED
(Jun 1, 2026)
PHASE1
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer Incyte Corporation NA COMPLETED
(May 1, 2026)
PHASE3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Incyte Corporation NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors Incyte Corporation NA TERMINATED
(May 1, 2026)
PHASE1, PHASE2
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Incyte Corporation NA RECRUITING
(May 1, 2026)
PHASE3
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Incyte Corporation NA TERMINATED
(Apr 1, 2026)
PHASE2


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Incyte Corp News

Incyte's Aspirations in Europe Get Significant Regulatory Support - Ad-hoc-news.de

21 Feb, 2026

Limited Information Yet "Impenetrable" Safeguards: The Upholding of a Salt Form Patent in China

30 Jan, 2026

Exploring Incyte: The Impact of a Targeted Biotech Pipeline on the Future of Cancer Treatment and...

03 Jan, 2026

European Commission Greenlights Incyte's Minjuvi Combination Treatment for Relapsed Cases ... - GeneOnline

18 Dec, 2025

See More